Form 4 for CRL Charles River Laboratories
Accepted 2021-08-10 00:00:00 ET · period of report 2021-08-09 · accession 0001127602-21-023436 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2021-08-10 | 2021-08-09 | CRL | Smith David Ross | CFO, Corp. Executive VP | S - Sale | $407.40 | -1,750 | 14.4K | -11% | -$713.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-09 | S | D | 600 | $406.36 | 15,575 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $405.93 to $406.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2021-08-09 | S | D | 1,150 | $407.95 | 14,425 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $407.43 to $408.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |